1World Health Organization. Burden of Disease Statistics. April 11, 2011. http ://www.who.int/healthinfo/bod/en/index.html. 被引量：1
2Lopez AD, Mathers CD, Ezzati M, et al. Global Burden of Disease and Risk Factors. Oxford: Oxford University Press, 2006. 被引量：1
3Johnston SC, Hauser SL. Neurological disease on the global agenda. Ann Neurol, 2008, 64: A11-A12. 被引量：1
4Johnston SC, Rootenberg JD, Katrak S, et al. Effect of a US National Institutes of Health progamme of clinical trials on public health and costs. Lancet, 2006, 367: 1319-1327. 被引量：1
5National Institute of Neurological Disorders and Stroke. NINDS Common Data Elements. April 11, 2011. http ://www. commonda- t aelement s .ninds .nih.gov/defanlt .asp x. 被引量：1
6Simera I, Moher D, Hirst A, et al. Transparent and accurate reporting increases reliability, utility, and impact of your reserach: reporting guidelines and the EQUATOR Network. BMC Med, 2010, 8: 24. 被引量：1
7Loring DW, Lowenstein DH, Barbaro NM, et al. Corrnnon data elements in epilepsy research: development and implementation of the NINDS epilepsy CDE project. Epilepsia, 2011, 52:1186-1191. 被引量：1
8National Institute of Neurological Disorders and Stroke. General CDE Standards. April 11,2011. http://www ninds.nih.gov/General.asp x. 被引量：1
9Laskowitz DT, Kasner SE, Saver J, et al. Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke, 2009, 40: 77-85. 被引量：1
10Whiteley W, Chong WL, Sengupta A, et al. Blood markers for the progaosis of ischemic stroke: a systematic review. Stroke, 2009, 40: e380-e389. 被引量：1
